Laurie Sehn

7:45
Novel targets and agents for lymphoma
John Kuruvilla et al.
5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn
Novel lymphoma targets and agents
Andrew Zelenetz et al.
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
1:06
Recognizing the heterogeneity of DLBCL
Laurie Sehn
1:34
The standard of care for DLBCL and double-hit lymphoma
Laurie Sehn
3:06
Results of trial on the use of interim PET scan to identify DLBCL
Laurie Sehn
The content of VJHemOnc is intended for healthcare professionals